Results 171 to 180 of about 9,594,514 (288)

Greener active pharmaceutical ingredients: perspectives of European healthcare professionals. [PDF]

BMC Health Serv Res
Puhlmann N, Heni Y, Vidaurre R, Moermond CTA, Kümmerer K, Sikanen TM, Olsson O.   +6 more
europepmc   +1 more source

Unveiling opportunities and challenges for a circular approach to macaúba biorefining: a technological roadmap

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The macaúba fruit, native to tropical and subtropical regions, has received considerable attention in recent years as a promising raw material for the production of advanced biofuels in Brazil. However, the development of large‐scale biomass requires overcoming significant challenges, such as designing circular biorefineries.
Fábio de A. Oroski, Flávia C. Alves, Maristela D. F. Freitas, José Vitor Bomtempo   +3 more
wiley   +1 more source

An Industry Perspective on Compassionate Use in Europe: A Call for Change. [PDF]

Ther Innov Regul Sci
Schlatter P, Heiss N, Franco P, Martin AO, Robson S, Reichenbach R.   +5 more
europepmc   +1 more source

Bioeconomy, sustainability, and digital technologies in Haematococcus lacustris biomass and astaxanthin production: advances and outlook

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Astaxanthin is a carotenoid with strong antioxidant properties, used in research on cancer treatment, ocular injuries, and neurological disorders. When produced by the microalgae Haematococcus lacustris, its antioxidant potential is even higher than that of the synthetic molecule, making it particularly attractive for pharmaceutical and ...
Renata Kühl Rocha, Lucas Nascimento Dario, Ana Caroline de Souza Barnabé, Paulo Sérgio de Arruda Ignácio, Reinaldo Gaspar Bastos, Augusto Ducati Luchessi   +5 more
wiley   +1 more source

Challenges in applying the EU AI act research exemptions to contemporary AI research. [PDF]

NPJ Digit Med
Meszaros J, Huys I, Ioannidis JPA.
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Deepfake-induced harm and AI accountability: a layered civil-liability framework for generative models, platforms, and digital identity. [PDF]

Front Artif Intell
Abousud EA.
europepmc   +1 more source

Comparison of measured and modeled data for carcinogen workplace exposure assessment: a case study on chromium trioxide under REACH and OSH frameworks. [PDF]

Ann Work Expo Health
Zellino C, Schlüter U, Wree R, Dumke AC, Walendzik G, Marelli C, Pagani E, Del Vecchio RL, Carminati A, Rovelli S, Fanti G, Borghi F, Cattaneo A, Spinazzè A, Cavallo DM.   +14 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Legal and ethical reflections on the use of artificial intelligence in the diagnosis and treatment of cancer: who assumes responsibility? [PDF]

Front Artif Intell
Prunoiu VM, Juverdeanu O, Cosma C, Laurentiu S, Strâmbu V, Petru AR, Stana M, Brătucu MN.   +7 more
europepmc   +1 more source